Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions highlight the findings of the clinical trials, with phrases like 'Ofatumumab associated with lower annualized relapse rates than teriflunomide' and 'very good news for #PwMS' signaling a positive response. The use of specific percentages related to efficacy and mentions of patient benefit contribute to an enthusiastic tone, reflecting a high level of interest and perceived importance regarding these treatment advancements.
The majority of posts show unanimous support for the findings, highlighting the superiority of ofatumumab over teriflunomide.
Discussions reflect high interest, as many users are eager to share insights and personal perspectives on the new treatment options.
Several posts engage deeply with the study results, discussing specific metrics like annualized relapse rates and disability progression.
Participants clearly perceive this publication to have a significant impact on treatment options for multiple sclerosis patients.
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutaneous. A new option for the treatment of #MS. Happy to have contributed. @vallhebron @VHIR_ @cemcat_em https://t.co/syVHf9nitO
En pacientes con ESCLEROSIS MÚLTIPLE, el uso de Ofatumumab se asoció con tasas de recaída anuales más bajas, comparado con la Teriflunomida. NEJM 2020; DOI: 10.1056/NEJMoa1917246 https://t.co/RLPrkUJ9RP
日本でも治験が行われているオファツムマブの第三相試験の結果が報告されました。日本で未承認のteriflunomideとの比較試験でしたが、有意差を持って優位性が示されました。#多発性硬化症 #オファツムマブ Ofatumumab versus Teriflunomide in Multiple Sclerosis https://t.co/akKASLwoe0
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM #esclerosis múltiple. Nos complace haber contribuido a este ensayo clínico @biocrucesHRI @GurutzetakoOsp. #ASCLEPIOS Gracias a nuestros pacientes que participaron en el estudio https://t.co/wcAMfNo88P
Best Multiple Sclerosis Medicine for Preventing Disability https://t.co/NstdJp9unx https://t.co/qeonuzaRZy
Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) are two treatments for multiple sclerosis targeting B cells. This video explains the differences between these drugs based on clinical trial results, addressing efficacy…
This video analyzes the results of randomized controlled trials involving multiple sclerosis treatments, focusing on their effectiveness in preventing disability progression. Key findings reveal that ofatumumab…
https://t.co/odnelf2428 Multiple expensive medications compared
RT @Brandon_Beaber: Best Multiple Sclerosis Medicine for Preventing Disability https://t.co/NstdJp9unx https://t.co/qeonuzaRZy
RT @Brandon_Beaber: Best Multiple Sclerosis Medicine for Preventing Disability https://t.co/NstdJp9unx https://t.co/qeonuzaRZy
RT @Brandon_Beaber: Best Multiple Sclerosis Medicine for Preventing Disability https://t.co/NstdJp9unx https://t.co/qeonuzaRZy
RT @Brandon_Beaber: Best Multiple Sclerosis Medicine for Preventing Disability https://t.co/NstdJp9unx https://t.co/qeonuzaRZy
Best Multiple Sclerosis Medicine for Preventing Disability youtu.be/3wstm5izx2o?...
Best Multiple Sclerosis Medicine for Preventing Disability https://t.co/NstdJp9unx https://t.co/qeonuzaRZy
https://t.co/hrMNAwW0Lx
RT @Brandon_Beaber: @themsguide @drbarrysinger @NEJM @KlausSchmierer @C_OrejaGuevara @AaronBosterMD By comparison the mean number of gad+ l…
@themsguide @drbarrysinger @NEJM @KlausSchmierer @C_OrejaGuevara @AaronBosterMD By comparison the mean number of gad+ lesions in the ASCLEIOS I/II trials for kesimpta was only 0.01 and 0.03 compared to 0.45 and 0.51 for Aubagio, so I strongly suspect kesimpta is better at suppressing gad+ lesions than this new drug.. https://t.co/0EM4WrNtbC https://t.co/C5LQq63tEb
RT @FPFabrizioPhD: Alcune fonti qui per approfondire (ne ho selezionate alcune): https://t.co/K0SnnOa8e3 https://t.co/ADhOpzV7le https://t.…
Alcune fonti qui per approfondire (ne ho selezionate alcune): https://t.co/K0SnnOa8e3 https://t.co/ADhOpzV7le https://t.co/PuxdrG3RIo 6/6 FINE
@semodough Ocrevus vs Aubagio. Somehow similar to $TGTX. Is $TGTX results sufficient to be differentiated? Not sure. https://t.co/qp5hKxfCkj
Results from the two identical phase 3 studies of a B-cell therapy for multiple sclerosis were recently published in the New England Journal of Medicine. Read more here: https://t.co/yCuFkSv4E0. https://t.co/CVQzL8toYu
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM https://t.co/MFrkFTEMOh
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM https://t.co/IOKXC1Yl5Q
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM https://t.co/JTjXmkDQsd
RT @DKFBasel: DKF Forschungsgruppenleiter Prof. Ludwig Kappos (@UniSpitalBasel) und Prof. Stephen Hauser (@UCSF) konnten in zwei Phase-III-…
DKF Forschungsgruppenleiter Prof. Ludwig Kappos (@UniSpitalBasel) und Prof. Stephen Hauser (@UCSF) konnten in zwei Phase-III-Studien die Überlegenheit von Ofatumumab gegenüber Teriflunomid bei #MultipleSklerose Patienten belegen. Publikation im @NEJM: https://t.co/P9tX47HYHO
RT @NeuroCRU: New results from @NeuroCRU study published in #NEJM. #Ofatumumab associated with lower annualized relapse rates than current…
New results from @NeuroCRU study published in #NEJM. #Ofatumumab associated with lower annualized relapse rates than current standard of care (teriflunomide) among patients with #MS taking part in the trial. https://t.co/Wc925Ea6eF @TheNeuro_MNI @McGillMed #multiplesclerosis https://t.co/7VnjF63Amk
RT @RevistaMFSamfyc: Ofatumumab frente a teriflunomida en la esclerosis múltiple https://t.co/g7BOo7DMlY PMID 32757523
Ofatumumab frente a teriflunomida en la esclerosis múltiple https://t.co/g7BOo7DMlY PMID 32757523
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
RT @FarmaCHUAC:
RT @FarmaCHUAC:
RT @FarmaCHUAC:
RT @FarmaCHUAC:
RT @FarmaCHUAC:
RT @FarmaCHUAC:
RT @FarmaCHUAC:
RT @AmbrizMau: En pacientes con ESCLEROSIS MÚLTIPLE, el uso de Ofatumumab se asoció con tasas de recaída anuales más bajas, comparado con l…
@Mustann20 @semodough https://t.co/ko8EFaB5vV
Sclérose en plaques, avancée majeure : Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. https://t.co/PwLmMAS3WL
RT @mendibe_mar: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM #esclerosis múltiple. Nos complace haber contribuido a este…
Recent #study examined the relative effects of two #MS treatments. Results showed that ofatumumab correlated with lower annualized relapse rates than teriflunomide. Read more: https://t.co/MJCwbIUaCA
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM https://t.co/VVG73nqxCe https://t.co/z5Z8fPTNIV
RT @AmbrizMau: En pacientes con ESCLEROSIS MÚLTIPLE, el uso de Ofatumumab se asoció con tasas de recaída anuales más bajas, comparado con l…
RT @AmbrizMau: En pacientes con ESCLEROSIS MÚLTIPLE, el uso de Ofatumumab se asoció con tasas de recaída anuales más bajas, comparado con l…
RT @AmbrizMau: En pacientes con ESCLEROSIS MÚLTIPLE, el uso de Ofatumumab se asoció con tasas de recaída anuales más bajas, comparado con l…
RT @AmbrizMau: En pacientes con ESCLEROSIS MÚLTIPLE, el uso de Ofatumumab se asoció con tasas de recaída anuales más bajas, comparado con l…
RT @AmbrizMau: En pacientes con ESCLEROSIS MÚLTIPLE, el uso de Ofatumumab se asoció con tasas de recaída anuales más bajas, comparado con l…
En pacientes con ESCLEROSIS MÚLTIPLE, el uso de Ofatumumab se asoció con tasas de recaída anuales más bajas, comparado con la Teriflunomida. NEJM 2020; DOI: 10.1056/NEJMoa1917246 https://t.co/RLPrkUJ9RP
RT @alfonso_casi: Ofatumumab versus teriflunomida en la esclerosis múltiple: En los pacientes con esclerosis múltiple, el ofatumumab se aso…
Ofatumumab versus teriflunomida en la esclerosis múltiple: En los pacientes con esclerosis múltiple, el ofatumumab se asocia con tasas de recaída anualizadas más bajas que la teriflunomida. https://t.co/inMz99rb4v
https://t.co/8AuzdhN2M2 NEJM : Research Ofatumumab versus Teriflunomide in Multiple Sclerosis The pathophysiology of multiple sclerosis involves B cells. Anti-CD20 monoclonal antibodies that induce B-cell depletion, such as rituximab and ocrelizumab, are effective diseas…
https://t.co/dPbLaDyUuh
Ofatumumab versus Teriflunomide in Multiple Sclerosis. https://t.co/021yKsuiGX
Ofatumumab versus Teriflunomide in Multiple Sclerosis. https://t.co/InfSntQnrD https://t.co/M9jAVkpPfg
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM https://t.co/K8ISP9rvbn
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @ichi580: 日本でも治験が行われているオファツムマブの第三相試験の結果が報告されました。日本で未承認のteriflunomideとの比較試験でしたが、有意差を持って優位性が示されました。#多発性硬化症 #オファツムマブ Ofatumumab versus Teri…
New article: Ofatumumab versus Teriflunomide in Multiple Sclerosis. https://t.co/6cZYF51a8k #MS #multiplesclerosis #neurology https://t.co/9H51uvIBZV
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @garinho29: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM A new option treatment for patients with multiple sclerosis. h…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @ichi580: 日本でも治験が行われているオファツムマブの第三相試験の結果が報告されました。日本で未承認のteriflunomideとの比較試験でしたが、有意差を持って優位性が示されました。#多発性硬化症 #オファツムマブ Ofatumumab versus Teri…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
[Abstract Only] Randomized trial: Ofatumumab vs. Teriflunomide in multiple sclerosis – via @NEJM https://t.co/cTIZhbMCKU
RT @ichi580: 日本でも治験が行われているオファツムマブの第三相試験の結果が報告されました。日本で未承認のteriflunomideとの比較試験でしたが、有意差を持って優位性が示されました。#多発性硬化症 #オファツムマブ Ofatumumab versus Teri…
RT @ichi580: 日本でも治験が行われているオファツムマブの第三相試験の結果が報告されました。日本で未承認のteriflunomideとの比較試験でしたが、有意差を持って優位性が示されました。#多発性硬化症 #オファツムマブ Ofatumumab versus Teri…
Great news. Another efficacious B cell depleting therapy for MS. And it can be given subcutaneously.
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM https://t.co/c9Ixzp1DFl
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM https://t.co/Mp7FocTA1y
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @mendibe_mar: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM #esclerosis múltiple. Nos complace haber contribuido a este…
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM #esclerosis múltiple. Nos complace haber contribuido a este ensayo clínico @biocrucesHRI @GurutzetakoOsp. #ASCLEPIOS Gracias a nuestros pacientes que participaron en el estudio https://t.co/wcAMfNo88P
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @ichi580: 日本でも治験が行われているオファツムマブの第三相試験の結果が報告されました。日本で未承認のteriflunomideとの比較試験でしたが、有意差を持って優位性が示されました。#多発性硬化症 #オファツムマブ Ofatumumab versus Teri…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @ichi580: 日本でも治験が行われているオファツムマブの第三相試験の結果が報告されました。日本で未承認のteriflunomideとの比較試験でしたが、有意差を持って優位性が示されました。#多発性硬化症 #オファツムマブ Ofatumumab versus Teri…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @BrainSantpau: Los resultados de los ensayos ASCLEPIOS acaban de ser publicados. Muy buenas noticias para nuestros pacientes. Especialme…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM https://t.co/q8Dj7wQ1ak
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM A new option treatment for patients with multiple sclerosis. https://t.co/Cx1hAqxkyj
RT @BrainSantpau: Los resultados de los ensayos ASCLEPIOS acaban de ser publicados. Muy buenas noticias para nuestros pacientes. Especialme…
日本でも治験が行われているオファツムマブの第三相試験の結果が報告されました。日本で未承認のteriflunomideとの比較試験でしたが、有意差を持って優位性が示されました。#多発性硬化症 #オファツムマブ Ofatumumab versus Teriflunomide in Multiple Sclerosis https://t.co/akKASLwoe0
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
"Ofatumumab was associated with lower annualized relapse rates than teriflunomide" https://t.co/kvEPlOc1vR
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
RT @XMontalban: Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutane…
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM Very good news for #PwMS. A high efficacy drug now subcutaneous. A new option for the treatment of #MS. Happy to have contributed. @vallhebron @VHIR_ @cemcat_em https://t.co/syVHf9nitO
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM https://t.co/Lho5mpbTiD
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
En pacientes con esclerosis múltiple, ofatumumab se asociaría con menos recaídas anualizadas que teriflunomide https://t.co/1isr39dCZS
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
RT @drbarrysinger: #ASCLEPIOS I & II trials published. #Ofatumumab under skin every 4 weeks reduced relapses 51-58%, disability progression…
XM
MA
中
MM
SC
B
DB
CP
FF
D
NM
N
AM
U
DB
MS
N
AM
RM
R
M
SC
MB
JC
RB
BG
RP
LA
MV
GP
O
D
Q
KM
MM
JU
G
E
V
DP
SJ
ΑΣ
AP
TC
IS
AJ
RV
JP
Y
PN
M
JS
AG
O
M
CG
DC
Y
M
JA
CC
NR
NM
PB
DM
RM
PF
JE
PM
HK
ND
Ʌ
C
A
RM
LB
SF
岩老
DM
VR
CG
JU
LS
GÁ
O
SM
C
رA
CR
NN
A
LC
SM
Dا
RD
PN
CC
D
I
PN
RG
RP
GM
KS